Market Place
Sourcing Support
Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
11 Nov 2024 //
ACCESSWIRE
Hemogenyx Receives Investment From Prevail Partners
02 Oct 2024 //
ACCESSWIRE
Hemogenyx`s FLT3 Assay Ready For Phase I At MD Anderson
08 Sep 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
02 Sep 2024 //
ACCESSWIRE
Hemogenyx To Present At Macrophage-Directed Therapies Summit
29 Jul 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Posting of Annual Report & Notice of AGM
03 Jun 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
14 Feb 2024 //
ACCESSWIRE
Hemogenyx Announces Submission of Complete Response to Clinical Hold
16 Jan 2024 //
ACCESSWIRE
Hemogenyx Announces HEMO-CAR-T Process Qualification Run Completed
08 Jan 2024 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer
27 Nov 2023 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Half-Year Report
28 Sep 2023 //
ACCESSWIRE
Hemogenyx Pharma Announces Strategic Investment from Prevail Partners, LLC
18 Sep 2023 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CBR Patent Application Update
08 Sep 2023 //
ACCESSWIRE
Hemogenyx gets clarity on cause of FDA clinical hold on CAR-T
11 Jul 2023 //
FIERCE BIOTECH
Hemogenyx Pharmaceuticals PLC Announces Full FDA Review for HEMO-CAR-T IND
10 Jul 2023 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Submission of IND for HEMO-CAR-T
09 May 2023 //
ACCESSWIRE
Hemogenyx Announces Final Results for the Year Ended 31 December 2022
28 Apr 2023 //
ACCESSWIRE
Hemogenyx Announces Equity Incentive Pool Increase and Option Grant
28 Apr 2023 //
ACCESSWIRE
Hemogenyx Pharma PLC Announces HEMO-CAR-T Analytical Release Tests Completed
23 Mar 2023 //
ACCESSWIRE
Hemogenyx PLC Announces HEMO-CAR-T Process Qualification Run Completed
04 Jan 2023 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC - HEMO-CAR-T First PQ Run Completed
12 Dec 2022 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
29 Sep 2022 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Presentation at H.C. Wainwright
01 Sep 2022 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Appointment of Director of Quality
22 Aug 2022 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Appointment of Medical Director
10 Aug 2022 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces Director/PDMR Shareholding
30 May 2022 //
ACCESSWIRE
Hemogenyx Pharma announces Final Results for the Year Ended 31 December 2021
02 May 2022 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T pre-IND Meeting Request
16 Feb 2022 //
ACCESSWIRE
Hemogenyx, Selexis Will Advance AML CDX Bispecific Antibody to Human Trials
12 Jan 2022 //
BUSINESSWIRE
Hemogenyx Pharmaceuticals Announces Hemo-CAR-T partnership with WuXi ATU
22 Dec 2021 //
PHARMABIZ
Hemogenyx inks partnership with WuXi ATU to manufacture lentiviral vectors
21 Dec 2021 //
PHARMABIZ
Hemogenyx Pharmaceuticals Announces CDX Licence Agreement
13 Oct 2021 //
BIOSPACE
Hemogenyx Pharma secures new monoclonal antibody patent in U.S.
02 Sep 2021 //
SEEKING ALPHA
Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Update
04 Mar 2021 //
ACCESSWIRE
Hemogenyx PLC Announces Draw Down Under Financing Facility Agreement
03 Feb 2021 //
ACCESSWIRE
Hemogenyx Pharmaceuticals PLC Announces CAR-T Master Translational Agreement
05 Jan 2021 //
ACCESSWIRE
